Drug intelligence / Profile preview

SGA304A

Development stage: Preclinical
Lead developer: BMG Pharma
Administration: Subcutaneous

Overview

SGA304A is an injectable dermal filler currently in preclinical development by BMG Pharma for applications in aesthetic medicine. Specifically designated as a subcutis filler, the product is designed for injection into the subcutaneous layer of the skin to address volume loss and provide tissue contouring. As part of BMG Pharma's aesthetic medicine pipeline, SGA304A likely utilizes the company's core expertise in hyaluronic acid or other polymer-based tissue engineering technologies, although its specific chemical composition remains proprietary. The asset is intended to provide structural support and aesthetic enhancement through mechanical volume restoration.

Other names: SGA304A Filler SubcutisSGA-304A Filler SubcutisSGA 304A Filler Subcutis

Beyond the preview

Go deeper on SGA304A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGA304A.

Explore the full profile